Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News Event

October 8, 2026 - 08:18

Celcuity Inc. saw its shares drop 17.3 percent after the company announced two significant developments regarding its breast cancer treatment. The company confirmed that REVTORPYK, also known as gedatolisib, is now commercially available in the United States for eligible patients with HR-positive, HER2-negative advanced breast cancer who do not have a PIK3CA mutation.

Alongside the launch, Celcuity introduced REVTORPYK Support Services, a program designed to help patients and providers navigate access, reimbursement, and financial assistance. The company stated the service aims to reduce barriers to treatment and streamline the process for those seeking the therapy.

In addition to the commercial launch, Celcuity submitted a supplemental New Drug Application to the Food and Drug Administration. If approved, this filing would expand the prescribing label to allow physicians to use REVTORPYK regardless of a patient's PIK3CA tumor status. The submission also includes data intended to support broader clinical use across a larger patient population.

The stock decline suggests investors may have expected different timing or terms around the announcements. Market reaction often reflects concerns about competition, pricing, or the pace of regulatory review. Celcuity has not commented on the share movement. The company continues to work with regulators and payers as it rolls out the treatment and support program. Further updates are expected as the sNDA review progresses.